APRE vs EXAS · $10.4M cap vs rev $2.76B
Aprea Therapeutics Inc (APRE) versus EXACT Sciences Corporation (EXAS) — a side-by-side from cached financials, not a winner call.
Aprea Therapeutics Inc (APRE) is a biotechnology company listed on US.
EXACT Sciences Corporation (EXAS) is a diagnostics & research company listed on NASDAQ.
APRE does not have a complete income-statement cache yet.
Latest reported EXAS revenue for 2024-12-31 was $2.76B. Net income was -$1.03B. Revenue was up 10.4% from 2023-12-31 to 2024-12-31. EXAS currently screens at market cap $20.03B.
APRE currently screens at market cap $10.4M. EXAS currently screens at market cap $20.03B.
Not investment advice. Open the APRE and EXAS stock pages for the full models.
Not investment advice.